Premium
Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapy
Author(s) -
Rabadi Sami J.,
Haid Max,
Scanlon Edward F.,
Khandekar Janardan D.,
Caprini Joseph A.,
Oviedo Miguel A.,
Cunningham Myles P.,
Grizenko Kerry K.,
Cohen Eli
Publication year - 1984
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930260407
Subject(s) - medicine , chemoimmunotherapy , adjuvant , cyclophosphamide , hormonal therapy , fluorouracil , regimen , adjuvant therapy , oncology , surgery , salvage therapy , chemotherapy , gastroenterology , breast cancer , cancer
Between July 1975 and June 1979, 194 patients with State II or III breast carcinoma were randomized to receive either L‐phenylalanine mustard (L‐PAM), cyclophosphamide and 5‐fluorouracil and prednisolone (CFP), or CFP and BCG. Sixty‐one patients have recurred despite the adjuvant chemoimmunotherapy trial. Fifty‐three are evaluable for survival and 36 for response to chemo‐hormonal therapy. Those treated with a chemo‐hormonal regimen for their first recurrence exhibited a 53% objective response rate to cytotoxic therapy or a 35% response to hormonal therapy. Prior exposure to L‐PAM, cyclophosphamide, or 5‐fluorouracil did not preclude response to ‘salvage’ therapy regimens containing those agents. Neither menopausal status, estrogen receptor content, size of the primary tumor, adjuvant treatment, nor extent of the recurrence had any effect on subsequent survival. Overall, the entire group exhibitied median survival of 37 months from initial diagnosis and 13 months from recurrence. Unlike recurrent Hodgkin's disease, there was no demonstrable relationship between the length of the disease‐free interval and the likelihood of subsequent response to cytotoxic or hormonal treatment. Comparison is made to the results of ‘salvage’ therapy administered after three other large adjuvant treatment series.